Texas Children’s Cancer and Hematology Centers is now open to enrollment in SARC024 (Regorafenib/Refractory Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcomas). SARC024 sites include:

• Atrium Health Levine Cancer Institute (Atlanta, GA)
• Children’s Hospital of Los Angeles
• Mayo Clinic (Jacksonville, FL)
• Mayo Clinic (Rochester, MN)
• Ohio State University (Columbus, OH)
• Oregon Health and Sciences University (Portland, OR)
• Texas Children’s Hospital (Houston, TX)
• Vanderbilt University (Nashville, TN)

Click the button below to learn more about this study and to view Dr. Maki’s SARC024 presentation at the 2021 SARC Semiannual Meeting.